Sometimes a company just puts together the complete package. Tactile Systems Technology, Inc. (TCMD) managed exactly that on Wednesday, sending shares up more than 23% in premarket trading after announcing both a strategic acquisition and earnings that made Wall Street's estimates look conservative.
The medical technology company revealed it's buying LymphaTech, a move designed to strengthen its position in the lymphedema treatment market. But the real kicker was the fourth-quarter results that came alongside the deal announcement.
Why LymphaTech Matters
The acquisition, announced Tuesday, involves an upfront cash payment of $6.8 million. There's also potential additional consideration tied to future milestones, though the company didn't spell out those specifics.
Here's what Tactile is actually getting: LymphaTech brings handheld device technology that delivers precise measurements of fluid volume and circumference in patients. That's important because lymphedema, the chronic swelling usually in arms or legs caused by a damaged or blocked lymphatic system, is notoriously difficult to diagnose and monitor accurately. The condition often results from cancer treatment like lymph node removal or radiation, though it can also stem from inherited or congenital issues.
The acquisition should enhance Tactile's ability to provide more accurate disease identification and treatment options for lymphedema patients, which fits neatly into their existing product lineup.
The Numbers That Got Everyone's Attention
Tactile Systems reported fourth-quarter earnings of 46 cents per share, edging past the consensus estimate of 44 cents. Nice, but not earth-shattering on its own.
The revenue number, though? That's where things got interesting. Sales jumped 21% year-over-year to $103.59 million, absolutely crushing Wall Street's estimate of $93.80 million. The beat came from strength across both lymphedema and airway clearance product lines.
Gross profit increased 26% to $81 million. Operating income nearly jumped 50% from $12.5 million to $18.8 million. Adjusted EBITDA hit $22.9 million compared to $16.2 million a year ago. Those are the kind of margins that get investors excited about operational leverage kicking in.
Looking Ahead to 2026
Management clearly feels confident. Tactile Systems is guiding fiscal 2026 sales between $357 million and $365 million, comfortably above the consensus estimate of $347.94 million. They're expecting adjusted EBITDA in the range of $49 million to $51 million.
That guidance suggests management sees the momentum continuing, which makes sense given the LymphaTech acquisition should start contributing during the year.
What the Charts Say
The technical picture has been strong even before Wednesday's pop. The stock was trading 21.5% above its 20-day simple moving average and 19.8% above its 100-day SMA, demonstrating solid short-term momentum. Shares are up 57.05% over the past 12 months and are currently positioned much closer to their 52-week highs than lows.
The RSI sits at 48.93, which is neutral territory and indicates no immediate overbought or oversold conditions. The MACD is below its signal line, suggesting some bearish pressure, though that seems less relevant given Wednesday's surge. The combination suggests mixed momentum, at least before the latest news.
Key resistance sits at $36.00, with support around $32.00.
Wall Street Weighs In
Analysts have been warming to the story. The stock carries a Buy rating with an average price target of $31.38, though that was set before Wednesday's move and will likely get revised higher.
Recent analyst actions include BTIG maintaining a Buy rating and raising their target to $38.00 on February 18. Piper Sandler upgraded the stock to Overweight with a $35.00 target on January 5. Lake Street has a Buy rating with a $32.00 target from November 4, 2025.
The Scorecard
Looking at the broader metrics, Tactile Systems shows some interesting characteristics. The Value score of 64.05 suggests the stock is trading at a reasonable valuation relative to peers, though probably not screaming cheap. The Quality score of 80.91 indicates a strong balance sheet and solid operational efficiency, which the recent margin expansion certainly supports.
The Momentum score of 94.33 tells you everything you need to know about recent performance. The stock has been significantly outperforming the broader market.
The verdict? Strong momentum backed by improving fundamentals, though investors should be aware they're paying up a bit for the growth story. Given the guidance beat and strategic acquisition, that premium might be justified.
Shares hit $34.60 in premarket trading Wednesday, marking a new 52-week high and validating the bull case, at least for now.
